Caligan Partners portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Caligan Partners reported a $2.1 bn portfolio of 25 positions to the SEC as of the end of Q2 2026. Its largest positions are LQDA, RVMD, ABVX. During the quarter it opened Immunocore Holdings and Viridian Therapeutics and exited Mineralys Therapeutics and Spyre Therapeutics.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Caligan Partners has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
- 13GCellectar BiosciencesCLRB5.9 %
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
What changed this quarter
21 positions with a change (5 new, 9 added to, 3 trimmed, 4 sold). 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Mineralys Therapeutics−3.6 ppof portfolioSold out5.3% → —
- Revolution Medicines+19%more sharesIncreased11.4% → 17.7%
- Spyre Therapeutics−2.1 ppof portfolioSold out3.1% → —
- Immunocore Holdings+2.1 ppof portfolioNew— → 2.1%
- Viridian Therapeutics+1.9 ppof portfolioNew— → 1.9%
- Xenon Pharmaceuticals−36%fewer sharesReduced5.7% → 2.6%
- Aura Biosciences+1,770%more sharesIncreased0.1% → 1.5%
- Avalo Therapeutics+94%more sharesIncreased1.7% → 2.8%
- MBX Biosciences−76%fewer sharesReduced1.8% → 0.5%
- Sagimet Biosciences+0.9 ppof portfolioNew— → 0.9%
- Maze Therapeutics−0.9 ppof portfolioSold out1.3% → —
- Artiva Biotherapeutics+0.8 ppof portfolioNew— → 0.8%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- LiquidiaLQDA31.2%
- Revolution MedicinesRVMD17.7%
- AbivaxABVX10.0%
- VaxcytePCVX6.1%
- ExelixisEXEL4.1%
- Tango TherapeuticsTNGX3.8%
- Avalo TherapeuticsAVTX2.8%
- Xenon PharmaceuticalsXENE2.6%
- ADMA BiologicsADMA2.3%
- LB PharmaceuticalsLBRX2.3%
- Immunocore HoldingsIMCR2.1%
- Viridian TherapeuticsVRDN1.9%
- Vor BiopharmaVOR1.7%
- SAB BiotherapeuticsSABS1.5%
- InventivaIVA1.5%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 25
Q2 2026: 83%
Q2 2026: 12.1%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Declared options (3)
Besides stocks, Caligan Partners declared 3 calls (they gain if it rises) with a notional of $53.0M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- CALLRevolution MedicinesRVMD$47.2M
- CALLAgios PharmaceuticalsAGIO$3.3M
- CALLAdma BiologicsADMA$2.5M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of May 29, 2026 (high confidence).
The data, as reported: CALIGAN PARTNERS (CRD 289887): 7.B private funds: 3 hedge (gross assets $988M); 5.D assets by client type: pooled vehicles 100% (of $1.3 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Abrams Bison InvestmentsInvestment firm · $2.0 bn
- Bowie Capital ManagementInvestment firm · $2.0 bn
- EcoR1 CapitalInvestment firm · $2.0 bn
- Voss CapitalInvestment firm · $2.0 bn
- Casdin CapitalInvestment firm · $2.0 bn
- CUSHING ASSET MANAGEMENT, LP dba NXG INVESTMENT MANAGEMENTInvestment firm · $2.2 bn